Namni Goel of the School of Medicine comments on a possible connection between genetics and sleepiness.
John Trojanowski and Jason Karlawish of the School of Medicine discuss research developments.
Kathleen Hall Jamieson of the Annenberg Public Policy Center comments on how polling data show that “President Obama now owns the economy.”
The still unresolved case of Marc Hauser, the researcher accused by Harvard of scientific misconduct, points to the painful slowness of the government-university procedure for resolving such charges. It also underscores the difficulty of defining error in a field like animal cognition where inconsistent results are common.
A survey conducted by the Annenberg Adolescent Communication Institute is cited.
Taking a cue from the world of business-performance experts and baseball talent scouts, Penn Medicine translational medicine researchers are among the first to find a way to measure the productivity of collaborations in a young, emerging institute. They published their findings the most recent issue of Science Translational Medicine.
Finding a drug that can cross the blood-brain barrier is the bane of drug development for Alzheimer’s disease and other neurological disorders of the brain. A new Penn study, published this week in the Journal of Neuroscience, has found and tested in an animal model of Alzheimer’s disease a class of drug that is able to enter the brain, where it stabilizes degenerating neurons and improves memory and learning.
Victor Galli and Leah Abrams, students in the School of Arts Sciences, and Ian Penkala, a student in the School of Engineering and Applied Science, discuss Penn’s vegetarian dining options.